Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 7 5 versus DEXMETHYLPHENIDATE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 7 5 versus DEXMETHYLPHENIDATE HYDROCHLORIDE.
ADDERALL 7.5 vs DEXMETHYLPHENIDATE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADDERALL 7.5 is a combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action involves blocking the reuptake of norepinephrine and dopamine into presynaptic neurons, as well as increasing their release into the extraneuronal space. This leads to increased levels of these neurotransmitters in the synaptic cleft, enhancing stimulation of postsynaptic receptors.
Dexmethylphenidate is a central nervous system (CNS) stimulant. Its mechanism of action in ADHD is not fully understood, but it is believed to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
5-20 mg orally 1-3 times daily; immediate-release tablets administered upon awakening and at 4-6 hour intervals as needed; extended-release capsules administered once daily upon awakening; maximum total daily dose 40 mg.
Initial: 5 mg orally twice daily (morning and noon) with or without food; titrate in increments of 5 mg weekly; maximum 20 mg twice daily (40 mg/day).
None Documented
None Documented
The terminal elimination half-life of amphetamine is approximately 10-13 hours in adults, but can vary based on urinary pH (alkaline urine prolongs half-life up to 20 hours; acidic urine reduces it to 7-8 hours). In children, half-life is slightly shorter (6-8 hours). Clinical context: Steady-state is achieved within 2-3 days.
2-4 hours (immediate-release); 4-5 hours (extended-release); clinical context: short half-life necessitates multiple daily dosing for immediate-release formulations
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites (including deaminated and hydroxylated products). Fecal excretion is negligible (<5%).
Renal (78-97% as metabolites and unchanged drug, with approximately 50% as de-esterified metabolites and 30% as unchanged drug)
Category C
Category A/B
CNS Stimulant
CNS Stimulant